26 / 74 · 1:10 · Original AXON film
Cagrilintide
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Amylin analogue
Amylin is part of the body’s meal-related signaling. Cagrilintide was designed as a long-acting amylin analogue, and researchers have tested it for weight management. [1]
Monotherapy and combination are distinct
This topic includes human randomized trials. A phase two study tested cagrilintide alone, while later phase three studies examined a combination with semaglutide called CagriSema. [1] [2]
Read benefits and adverse events together
The studies reported weight reductions, alongside adverse effects, particularly gastrointestinal symptoms. A combination’s results cannot be assigned to cagrilintide alone or to an unverified online product. [1] [2]
Status checked: 5 November 2026
At this script’s November 2026 review, the sponsor still described CagriSema as unapproved in the United States. Regulatory status must be checked again before publication. [3]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Lau et al. (2021): Randomized phase 2 cagrilintide trial →Amylin rationale, monotherapy trial, weight and adverse-event findings.
- Garvey et al. (2025): Coadministered cagrilintide and semaglutide in adults with overweight or obesity →CagriSema combination trial; not interchangeable with cagrilintide monotherapy.
- Novo Nordisk October 2026 update and US regulatory disclosure →US application submitted; decision expected Q4 2026; product described as unapproved.
